Archived ASX Releases

2009 Releases

CSL Limited and National Blood Authority sign new Australian Fractionation Agreement
CSL Limited (ASX: CSL) announced today that it has signed an agreement with the National Blood Authority, acting on behalf of both State and Commonwealth Governments, to continue to provide the Australian community with safe, secure and affordable plasma therapeutic products. More.

CSL Limited (ASX:CSL), Australia’s leading biopharmaceutical company, announced today a number of changes in its organisation structure and its senior executive group, within the context that Dr Brian McNamee would be continuing as CEO and Managing Director for at least a further three to four years. More.

Full-year results for 2008/09
CSL Limited today announced a profit after tax of $1.15 billion for the twelve months ended 30 June 2009, up 63% when compared to the twelve months ended 30 June 2008. More.

Accounting treatment – conversion of USD$1.5 billion funds on deposit to Australian dollars
On 9 June 2009, CSL Limited (ASX:CSL) made an announcement to the Australian Securities Exchange regarding the termination of the Talecris Biotherapieutics merger agreement. More.

Recording of Analyst Briefing
Analyst Briefing with CSL Managing Director and Chief Executive Officer, Dr Brian McNamee. This was recorded on June 9th 2009 following the announcement that CSL and Talecris Biotherapeutics have agreed to terminate the merger agreement. More.

CSL and Talecris Biotherapeutics Agree to Terminate Merger Agreement
CSL Limited (ASX: CSL) and Talecris Biotherapeutics, Inc. announced today that they have mutually agreed to terminate their merger agreement, announced on August 12, 2008, under which CSL agreed to acquire Talecris for US$3.1 billion in cash. More.

CSL announces on-market share buyback
CSL Limited (ASX:CSL) today announced its intention to conduct an on-market share buyback of up to 54,863,000 shares1. This represents approximately 9% of the company’s current shares on issue. At an assumed price per share of approximately A$29 (being CSL's last closing price on Friday 5 June), this would represent a total buy back consideration of up to A$1.59 billion. More.

CSL Receives USD180 million (approximately AUD230 million) Order from U.S. Government to Produce Novel Influenza A (H1N1) Vaccine
CSL Limited announced today that its US subsidiary, CSL Biotherapies, Inc., has signed a contract with the U.S. Department of Health and Human Services (HHS) to provide Novel A (H1N1) influenza vaccine antigen in bulk form. More.

Recording of Analyst Briefing
Analyst Briefing with CSL Managing Director and Chief Executive Officer, Dr Brian McNamee. More.

CSL Limited responds to FTC announcement
CSL Limited (ASX: CSL) today was informed that the US Federal Trade Commission (“FTC”) will file a complaint in the US Federal District Court to challenge CSL’s proposed acquisition of Talecris Biotherapeutics. More.

CSL meets with US Federal Trade Commissioners regarding Talecris Acquisition
CSL Limited today announced that Dr Brian McNamee met with the US Federal Trade Commission. More.

Proposed Acquisition of Talecris Biotherapeutics
CSL Limited has become aware of market and media speculation regarding the proposed acquisition of Talecris Biotherapeutics, Inc. More.

CSL Half-year Results Announcement for 2008/09
CSL Limited today reported a profit after tax of $502 million for the six months ended 31 December 2008, up 44% when compared to the six months ended 31 December 2007. This included a foreign currency benefit of $26 million and a number of favourable non operational items totalling $44 million in net profit after tax which also boosted the result. Adjusting for currency and the items above, underlying profit growth was 24%. More.

CSL Limited Change of Company Secretary
With immediate effect, Mr Edward Bailey is the company secretary of CSL Limited. More.

© 2017 CSL Limited